Publications by authors named "Jaroslaw Trebacz"
Background: The coexistence of mitral regurgitation (MR) and severe aortic stenosis (AS) has been associated with worse outcomes in patients undergoing transcatheter aortic valve implantation (TAVI). Herein, the aim was to assess the etiology and degree of MR in an unselected TAVI population and investigate the impact of MR reduction at mid-term follow-up.
Methods: Patients subjected to TAVI as a treatment for severe AS in a single center were retrospectively analyzed.
Introduction: Intricate management of heart failure (HF), especially in the context of reduced ejection fraction, is further complicated by an elevated risk of thromboembolic events. Studies published so far offer inconclusive insight into the interplay between mitral regurgitation (MR) and the coagulation system.
Objectives: This study aimed to investigate the impact of transcatheter edge‑to‑edge repair (TEER) on specific coagulation parameters in HF patients.
Article Synopsis
- * The study involved over 18,000 patients who were randomly assigned to receive either CSL112 or a placebo, showing that CSL112 resulted in a numerical decrease in rates of cardiovascular death and recurrent MIs over 1 year.
- * While CSL112 did not significantly meet the primary endpoint goals, the results suggest it may help reduce the risk of heart-related complications, indicating a potential benefit of apoA-I in managing cholesterol and plaque stability in at-risk patients.
Background: Cardiovascular events frequently recur after acute myocardial infarction, and low cholesterol efflux - a process mediated by apolipoprotein A1, which is the main protein in high-density lipoprotein - has been associated with an increased risk of cardiovascular events. CSL112 is human apolipoprotein A1 derived from plasma that increases cholesterol efflux capacity. Whether infusions of CSL112 can reduce the risk of recurrent cardiovascular events after acute myocardial infarction is unclear.
View Article and Find Full Text PDFArticle Synopsis
- Valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) is shown to be safe and effective, reducing the need for repeat surgical valve replacements in high-risk patients.
- In Poland, the proportion of ViV-TAVI procedures was about 2% of all TAVIs in 2020, with expectations for an increase in this number.
- The article discusses the challenges of ViV-TAVI, emphasizing the importance of pre-procedural planning to optimize outcomes and reduce risks, while also reviewing guidelines for repeat TAVI in cases of failed aortic bioprosthesis.
Balloon aortic valvuloplasty for severe aortic stenosis may reduce mitral regurgitation in mid-term follow-up.
Postepy Kardiol Interwencyjnej
September 2022
Introduction: Mitral regurgitation (MR) is a frequent complication in patients with severe aortic stenosis (AS).
Material And Methods: Echocardiographic assessment of MR was performed at baseline, at 30 days and at 6 months after balloon aortic valvuloplasty (BAV).
Results: Data of 271 patients were included in our final analysis, of which 21.
Introduction: Transcatheter aortic valve‑in ‑valve implantation (ViV‑TAVI) has emerged as an alternative to redo surgery in patients with failed surgical aortic bioprosthesis.
Objectives: We evaluated the safety and efficacy of ViV‑TAVI in Polish patients after surgical aortic valve replacement.
Patients And Methods: This was a nationwide multicenter registry of ViV‑TAVI procedures.
The study aimed to assess procedural complications, patient flow and clinical outcomes after balloon aortic valvuloplasty (BAV) as rescue or bridge therapy, based on data from our registry. A total of 382 BAVs in 374 patients was performed. The main primary indication for BAV was a bridge for TAVI ( 185, 49.
View Article and Find Full Text PDFTricuspid regurgitation (TR) is a common acquired valvular heart disease (VHD). TR has progressive character and is associated with impaired long-term survival in both symptomatic and asymptomatic subjects. Despite this knowledge, the overall number of tricuspid valve surgeries is very low worldwide and many patients with clear indications for intervention are left untreated.
View Article and Find Full Text PDFCardiac rehabilitation (CR) provides multifactorial support and intervention for cardiac patients and improves quality of life (QoL). We aimed to assess clinical performance and QoL changes in patients undergoing transcatheter aortic valve replacement (TAVR) scheduled directly to inpatient CR (CR group) and those who were discharged home (DH group). The following patient-related outcomes were recorded: 5 m walk time (5MWT), 6 min walk test (6MWT), handgrip strength (HGS) with dynamometer, Katz index of Independence of Activities in Daily Living (KI of ADL), Hospital Anxiety and Depression Scores (HADS) Score.
View Article and Find Full Text PDFBackground: Transfemoral approach (TFA) is the most common access route for transcatheter aortic valve implantation (TAVI). Percutaneous femoral access (PA) is preferred over the surgical approach (SA), however, may be associated with a higher risk of access site complications. Thus, we aimed to assess outcomes of computed tomography-guided tailored approach to percutaneous and surgical TFA in patients undergoing TAVI.
View Article and Find Full Text PDFIntroduction: Transapical access (TA) transcatheter aortic valve implantation (TAVI) (TA-TAVI) represents one of the possible routes in patients with severe aortic stenosis (AS) who are not suitable for transfemoral access.
Aim: To assess early- and mid-term clinical outcomes after TA-TAVI.
Material And Methods: Patients with severe symptomatic AS undergoing TA-TAVI from November 2008 to December 2019 were enrolled.